



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1646
Lars LANNFELT)	Examiner: O.N. CHERNYSHEV
Serial No.: 09/899,815)	Confirmation No. 9645
Filed: July 9, 2001)	Washington D.C.
For: PREVENTION AND)	September 3, 2002
TREATMENT OF...)	Docket No. LANNFELT 1A

15/D
M9J
9/12/02

**ELECTION, RESPONSE TO SEQUENCE LISTING REQUIREMENT,
AND AMENDMENT**

RECEIVED

Commissioner of Patents
Washington, D.C. 20231

SEP 06 2002
TECH CENTER 1600/2900

S i r :

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

In response to the paper mailed July 3, 2002, please enter the following amendment and remarks:

IN THE CLAIMS

Please rewrite claims 8, 17 and 19 to read as follows:

D1
8. (Amended) A peptide A β -Arc having the amino acid sequence disclosed in SEQ ID NO:1 comprising a glycine at position 22 instead of glutamic acid compared to wild type A β peptide.

D2
17. (Amended) A method for prevention or treatment of Alzheimer's Disease (AD), comprising the step: decreasing the formation of A β protofibrils and/or lower meric forms thereof in a subject having, or suspected of having, AD.

D3
19. (Amended) A method according to claim 17, wherein said step is by passive immunisation with antibodies against a non wild-type protofibril or compound(s) with protofibril forming ability.